Completed PHASE3 INTERVENTIONAL 3-arm NCT01804829

Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.

A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients

Sponsor: Biotest Pharmaceuticals Corporation

Conditions Hepatitis C Infection Hepatitis, Viral, Human Hepatocellular Carcinoma Liver Cirrhosis Viruses

Interventions Civacir® 10%

Updated 7 times since 2017 Last updated: Mar 14, 2017 Started: Jun 30, 2013 Primary completion: Feb 29, 2016 Completion: Jun 30, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01804829, this PHASE3 trial focuses on Hepatitis C Infection and Hepatitis, Viral, Human and remains completed. Sponsored by Biotest Pharmaceuticals Corporation, it has been updated 7 times since 2013, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Apr 2022 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Apr 2022 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Jun 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Biotest Pharmaceuticals Corporation

Data source: Biotest Pharmaceuticals Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Boston, United States , Burlington, United States , Charlottesville, United States , Chicago, United States , Dallas, United States , Houston, United States , Lexington, United States , Los Angeles, United States , Memphis, United States and 8 more locations